acute infection and sepsis test News
-
Inflammatix Appoints Amy Boyle as Chief Operating Officer
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021. Ms. Boyle brings 30 years of broad commercial medical device experience to the company, with expertise in strategy, market development, sales and marketing, commercial operations, and manufacturing. Most ...
-
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
Inflammatix, a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF ...
-
Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)
Inflammatix, a pioneering molecular diagnostics company, announced today that the National Institute of General Medical Sciences, part of the National Institutes of Health, has awarded the company a Small Business Innovation Research (NIH SBIR) Direct-to-Phase II grant of $1.7 million. The funding will be used to develop a rapid diagnostic that will identify immune subtypes ...
-
Inflammatix Appoints Dr. Kian Beyzavi as New Board Member
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors. Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis ...
-
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Inflammatix a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, to further develop its point-of-care test and system to diagnose infection by reading ...
-
Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test
Inflammatix, a pioneering molecular diagnostics company, announced today a contract extension of $12.1 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response. The funding is part of a BARDA contract worth up to $72 million if all options are ...
-
New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced findings from a new study published today in Nature Communications that demonstrate its ability to identify patients with bacterial versus viral infections using a data-driven approach that measures the immune system response. The molecular classifier used in the study forms the ...
-
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk
Inflammatix a pioneering molecular diagnostics company, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $1.1 million for further development of a rapid diagnostic that reads the immune system to predict severe respiratory failure risk in COVID-19 patients. The diagnostic is being developed to help physicians make better hospital admission ...
-
Inflammatix Appoints João Fonseca, Ph.D., as Chief Technology Officer
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced the appointment of João Fonseca, Ph.D., as Chief Technology Officer. Dr. Fonseca will oversee Inflammatix’s molecular assay development and engineering teams as the company advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification. ...
-
Inflammatix Announces $32 Million in Series C Funding
Financing will be used to advance HostDx tests for acute infections and sepsis to commercial launch in 2021. Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced a $32 million Series C financing. The funding round included participation from existing investors Khosla Ventures, Northpond Ventures and Think.Health Ventures, and ...
-
Study Demonstrates Substantial Cost Savings in Health Economic Model of the Inflammatix Host-Response Test for Sepsis
Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows use of the company’s HostDxTM Sepsis test in patients suspected of acute respiratory tract infections (ARTI) in Emergency Departments is cost-effective versus standard-of-care. The study was published today in The Journal ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you